Raghav Chari - Dr Reddys Senior Vice President - Proprietary Products

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:4em;padding-top: 15px;;'>DR</div>
RDY -- USA Stock  

USD 42.58  0.13  0.31%

  President
Dr. Raghav Chari is Executive Vice President and Head Proprietary Products of Dr. Reddy Laboratories Ltd. He was SENIOR VICEPRESIDENT PROPRIETARY PRODUCTS of the company. He heads Proprietary Products segment and is responsible for developing a viable portfolio of products across Company New Chemical Entities and Differentiated Formulations businesses. Dr. Chari joined the Company in 2006 as Vice President Corporationrationrate Development for Company New Chemical Entities and Specialty business and has helped shape Company Proprietary Products business strategy while developing alliance platforms. He started his career with McKinsey and Company, where he spent several years as an Associate, Engagement Manager and finally Associate Principal in McKinseys Pharmaceuticals and Medical Products practice. After McKinsey, he took leadership roles in strategy and business development with several smaller biotech companies. Prior to joining the Company, he was the head of the Corporationrationrate Strategy function at NPS Pharmaceuticals
Age: 45  President Since 2013  Ph.D    
91 40 4900 2900  http://www.drreddys.com
Chari is a graduate in Mathematics and Physics from the California Institute of Technology and holds a Ph.D in Theoretical Physics from Princeton University.

Management Efficiency

The company has Return on Asset of 6.98 % which means that on every $100 spent on asset it made $6.98 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 18.75 % implying that it generated $18.75 on every 100 dollars invested.
The company has 811.73 M in debt with debt to equity (D/E) ratio of 20.5 . This implies that the company may be unable to create cash to meet all of its financial commitments. Dr Reddys Laboratories has Current Ratio of 1.92 which is typical for the industry and considered as normal.

Similar Executives

Showing few of many executives

PRESIDENT Since

Stefan WeiskopfZoetis
2013
Charles WagnerVertex Pharmaceuticals Incorpor
2019
Reshma KewalramaniVertex Pharmaceuticals Incorpor
2018
James MichaudPerrigo Company Plc
2016
Jeffrey ChodakewitzVertex Pharmaceuticals Incorpor
2014
George YancopoulosRegeneron Pharmaceuticals
2016
Paul WeningerPerrigo Company Plc
2015
Peter PowchikRegeneron Pharmaceuticals
2006
Joyce LeeZoetis
2012
Roman TrawickiZoetis
2015
Sandra BeatyZoetis
2012
Michael StewartPerrigo Company Plc
2004
Michael PartridgeVertex Pharmaceuticals Incorpor
N/A
Douglas McCorkleRegeneron Pharmaceuticals
2007
Catherine KnuppZoetis
2012
John HendricksonPerrigo Company Plc
2016
Ian SmithVertex Pharmaceuticals Incorpor
2017
Alejandro BernalZoetis
2015
Heidi ChenZoetis
2012
Jatin ShahPerrigo Company Plc
2005
Ronald JanishPerrigo Company Plc
2015

Entity Summary

Reddys Laboratories Limited operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India. Dr Reddys operates under Drug ManufacturersSpecialty Generic classification in USA and is traded on BATS Exchange. It employs 21966 people.Dr Reddys Laboratories Ltd (RDY) is traded on BATS Exchange in USA and employs 21,966 people.

Dr Reddys Laboratories Leadership Team

G Prasad, Co-Chairman of the Board, Chief Executive Officer, Managing Director
MARC KIKUCHI, Chief Executive Officer, North America Generics
Hans Hasler, Additional Independent Director
Leo Puri, Non-Executive Independent Director
Sandeep Poddar, Compliance Officer, Company Secretary
Satish Reddy, Co-Chairman of the Board
Kedar Upadhye, IR Contact Officer
Samiran Das, Executive Vice President Head - FTO and GGPM
Sauri Gudlavalleti, Global Head of Integrated Product Development Organization
YUGANDHAR PUVVALA, Global Head of Supply Chain
Amit Biswas, Executive Vice President - Integrated Product Development
Ravi Bhoothalingam, Non-Executive Independent Director
Alok Sonig, Senior Vice President & India Business Head (Generics)
Allan Oberman, Non-Executive Independent Director
J Ramachandran, Executive Vice President-Management Systems and Corporate Initiatives
Prasad Menon, Lead Non-Executive Independent Director
K Rao, Sr. Vice President & Head ? Chemical Technical Operations (CTO)
Abhijit Mukherjee, COO
Anil Namboodiripad, Global Head of Proprietary Products
Saumen Chakraborty, President, Chief Financial Officer and Global Head of ITBPE, Legal & Compliance and FMCRE
SANJAY SHARMA, Global Head of Manufacturing
Shikha Sharma, Non-Executive Independent Director
Sridar Iyengar, Non-Executive Independent Director
Ganadhish Kamat, Executive Vice President and Global Head-Quality
Sripada Chandrasekhar, President, Global Head of HR and Member of Management Council
Omkar Goswami, Non-Executive Independent Director
Erez Israeli, Chief Operating Officer and Global Head of Generics & PSAI
Kalpana Morparia, Non-Executive Independent Director
Bharat Doshi, Non-Executive Independent Director
J Moreau, Non-Executive Independent Director
Raymond Vre, Global Head of Biologics
Raghav Chari, Senior Vice President - Proprietary Products
Bruce Carter, Non-Executive Independent Director
Saunak Savla, IR Contact Officer
Ashok Ganguly, Non-Executive Independent Director
Umang Vohra, Executive Vice President Head - North America Generics
M Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets)
Cartikeya Reddy, Senior Vice President Head - Biologics
Anupam Puri, Non-Executive Independent Director
Archana Bhaskar, Chief Human Resource Officer
Deepak Sapra, Global Head of PSAI